Tesamorelin Next to a GLP-1 for Visceral Fat: What Each Has Shown, and Why the Combination Is Untested
Tesamorelin's visceral-fat trials, what GLP-1-class agents do to visceral and liver fat, why the stack sounds logical, and the questions no trial has answered.
The community pairs tesamorelin with retatrutide, tirzepatide or semaglutide and asks whether it does anything a GLP-1-class agent alone would not. Tesamorelin's own visceral-fat, liver-fat and cognition evidence is covered in a separate article, its regulatory status in our buying guide, GH-axis side effects in a dedicated review, IGF-1 as its tracking biomarker in a separate explainer, and the GHRH-vs-GHRP distinction in our comparison article. This article stays on the combination question: what each agent has shown on visceral fat, liver fat and lean mass, why stacking them sounds logical, which interactions are physiologically plausible, and the fact that no trial has tested the two together. It contains no dosing, timing or stacking instructions and no claim that the combination works, is safe, or adds anything.
TL;DR: what is measured, and what is not
- Tesamorelin's visceral-fat effect is real, selective and measured almost entirely in HIV lipodystrophy. Every randomized trial but one enrolled HIV-infected adults with lipodystrophy, a specific pathophysiology; the one exception ran in non-HIV adults with reduced GH secretion, not the general population that stacks it with a GLP-1.
- Its own label calls it weight-neutral. EGRIFTA WR's prescribing information states it "is not indicated for weight loss management as it has a weight neutral effect," which sits next to trial data showing it reduces visceral fat without changing subcutaneous fat or BMI.
- GLP-1-class agents cut total fat, visceral fat and liver fat, with 25% to 39% of the weight lost coming from lean mass. That lean-mass loss is the community's stated reason for adding tesamorelin, which in its own trials produced a lean-mass gain instead of a loss.
- The stack rationale is a hypothesis built from two separate evidence bases, not a result. VAT selectivity plus a lean-mass difference is a plausible-sounding combination on paper; nobody has measured what actually happens when both are run together.
- Zero trials, zero registry entries. A ClinicalTrials.gov and PubMed search in August 2026 for tesamorelin combined with any GLP-1-class agent returned nothing.
Research use only
Tesamorelin and retatrutide are sold here as laboratory research materials, not as medicines, and not for administration to a person or animal. This article reviews what has and has not been studied about tesamorelin and GLP-1-class agents on visceral fat, liver fat and lean mass; it contains no dosing, timing, cycling or stacking instructions, and nothing here is a claim that combining these agents is effective, safe, additive or synergistic.
Modified GHRH analog for lipodystrophy and metabolic liver research
First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.
Growth hormone secretagogues and gonadotropins
What people are asking
Our own Reddit corpus, the 12 months to August 2026 across r/Peptides, r/Retatrutide, r/Biohackers, r/PeptideDiscussion, r/tirzepatidecompound and r/Semaglutide, is a community report, not a scientific sample: 2,216 posts mention tesamorelin, most of them in r/Peptides (882) and r/Retatrutide (645). Of those, 1,237 also mention a GLP-1-class agent (retatrutide, tirzepatide, semaglutide, or the term "GLP-1"), and 742 discuss stacking. YouTube content was not reviewed.
- Posts
- 1,237
- Posts
- 742
- Posts
- 866
- Posts
- 277
- Posts
- 202
- Posts
- 105
- Posts
- 104
- Posts
- 70
- Posts
- 67
- Posts
- 16
Within the 1,237 stack posts specifically, the themes shift toward the effects people are trying to separate out: 92 mention sleep, 89 mention appetite or hunger, 80 mention waist, inches or belly, 57 mention joint pain, water retention, carpal tunnel or numbness, 42 mention IGF-1, and 36 mention glucose, blood sugar or insulin.
A handful of threads illustrate the pattern, cited here by title only, as community reports rather than evidence. "6 Month Retatrutide + Tesamorelin" (168 upvotes) credits midsection fat loss and recovery to tesamorelin and appetite control and weight loss to retatrutide, while reporting mild nausea, occasional fatigue and early sleep fluctuations. "Our Peptide Stack After 7 Months. Down 83 lbs Combined" (445 upvotes) describes a couple on tirzepatide and retatrutide plus tesamorelin, ipamorelin, GHK-Cu and MOTS-c, combined with strength training and high-protein eating, too many simultaneous inputs for any one to be credited. Two threads describe reactions rather than results. "Sharing my tesamoralin experience that ended with me in hospital" (142 upvotes, 121 comments) describes whole-body itching, a metallic taste and vomiting after restarting tesamorelin together with other peptides, ending in a hospital visit, a single account. "What's one peptide you tried that you probably wouldn't run again?" (123 upvotes, 398 comments) contains a reply describing skin flushing, a racing heart and throat tightness after the first tesamorelin injections, called "borderline anaphylactic" by the poster.
The pattern is consistent: self-reports with several interventions starting together, no imaging and no control group, so no single agent's contribution can be isolated.
What tesamorelin has shown on visceral fat
The tesamorelin trials that used visceral adipose tissue (VAT) as their primary outcome were randomized and placebo-controlled.
- Population
- HIV-infected adults with excess abdominal fat, on antiretroviral therapy
- n
- 404
- Duration
- 26 weeks
- VAT result
- -10.9% (-21 cm2) vs -0.6% (-1 cm2) with placebo, P < 0.0001
- Population
- Antiretroviral-treated HIV-infected adults with abdominal fat accumulation
- n
- 50
- Duration
- 6 months
- VAT result
- -34 cm2 vs +8 cm2 with placebo (treatment effect -42 cm2, 95% CI -71 to -14, P = 0.005)
- Population
- People with HIV and NAFLD (hepatic fat fraction 5% or more)
- n
- 61
- Duration
- 12 months
- VAT result
- Not the primary VAT endpoint (see liver fat below)
- Population
- Abdominally obese adults WITHOUT HIV but with reduced GH secretion
- n
- 60
- Duration
- 12 months
- VAT result
- -16 vs +19 cm2 with placebo (treatment effect -35 cm2, 95% CI -58 to -12, P = 0.003)
Falutz et al. 2010, the largest tesamorelin trial (table above), also found trunk fat, waist circumference and waist-hip ratio improved, "no change in limb or abdominal SC fat," and IGF-1 rose significantly (P < 0.001) with "no change in glucose parameters."
Stanley et al. 2014, in JAMA, also measured liver fat by MRI lipid-to-water percentage, finding a net treatment effect of -2.9% (P = .003). Glucose moved the other way here: fasting glucose rose in the tesamorelin group at 2 weeks, a mean change of 9 mg/dL versus 2 mg/dL with placebo.
Stanley et al. 2019, in Lancet HIV, enrolled 61 people with HIV and NAFLD (hepatic fat fraction 5% or more) for 12 months. Hepatic fat fraction fell by an absolute 4.1% (95% CI -7.6 to -0.7, p = 0.018), a 37% relative reduction; 35% reached a hepatic fat fraction below 5%, against 4% on placebo.
Makimura et al. 2012, the only randomized tesamorelin trial outside HIV-associated lipodystrophy (table above), also found carotid intima-media thickness, C-reactive protein and triglycerides improved, with "no significant effects on abdominal sc adipose tissue." IGF-1 rose by 92 µg/L, with "no changes in fasting, 2-h glucose, or glycated hemoglobin" and no serious adverse events. The authors' conclusion: tesamorelin "selectively reduces VAT without significant effects on sc adipose tissue ... without aggravating glucose" in this population.
Two further studies looked past fat quantity. Lake et al. 2021, pooling two trials, compared 193 tesamorelin responders (a VAT decrease of 8% or more, about 70% of participants) against 148 placebo participants and found fat density, a quality marker, rose in both visceral fat (+6.2 vs +0.3 Hounsfield units) and subcutaneous fat (+4.0 vs +0.3), P < 0.0001. Adrian et al. 2019, same population, found in an exploratory analysis that trunk muscle density and area increased against placebo, density coefficients 1.56 to 4.86 Hounsfield units, all p < 0.005.
Two 2026 meta-analyses: Badran et al., pooling 5 RCTs, found VAT MD -27.71 cm2 (95% CI -38.37 to -17.06), trunk fat -1.18 kg, limb fat -0.22 kg, hepatic fat -4.28%, waist -1.61 cm, lean body mass +1.42 kg (95% CI 1.13 to 1.71), no significant change in subcutaneous fat or BMI, adverse events including "arthralgia, myalgia, paresthesia, and injection-site reactions," concluded as coming "without serious side effects or perturbation of glucose." Ditta et al., pooling 4 RCTs and 909 patients, found VAT MD -21.47 cm2 (95% CI -34.73 to -8.22, I2 = 74%), waist -1.61 cm, trunk fat -1.20 kg, lean body mass +1.42 kg, total cholesterol -0.16 mmol/L, but also "growth hormone-related adverse effects and higher discontinuation rates (RR 2.25, 95% CI 0.98 to 5.17, p = 0.06) were observed," closing that "limited data on long-term safety, optimal dosing strategies, and durability of treatment effects warrant caution."
Every tesamorelin RCT except Makimura 2012 was run in HIV-associated lipodystrophy, a specific pathophysiology tied to antiretroviral therapy. None was run in people losing weight on a GLP-1-class agent, the population actually stacking the two.
What the label says it is, and is not
EGRIFTA WR's US prescribing information (DailyMed setid 839334d3-8c1d-4c26-9036-2ab524a6ea75) states its indication plainly: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." Its limitation of use is just as plain: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." Read next to the VAT trial data above, this is consistent rather than contradictory: in the trials VAT decreased while subcutaneous fat did not change significantly, and the Badran 2026 meta-analysis found no significant change in BMI, whereas GLP-1-class agents reduce total fat mass. Regulatory history, including the withdrawn EU application, is covered in our buying guide.
The label's warnings and precautions section lists, on malignancy: "Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA WR." On IGF-1, which rose in Falutz 2010 and Makimura 2012: "Monitor IGF-1 levels during EGRIFTA WR therapy. Consider discontinuing in patients with persistent elevations." On fluid retention: it "may include edema, arthralgia, and carpal tunnel syndrome." On glucose: "Evaluate glucose prior to and during therapy," acknowledging the direction seen in Stanley 2014. On immune reactions: "hypersensitivity reactions have occurred in clinical trials." Injection-site reactions (erythema, pruritus, pain, irritation, bruising) are also listed, with a note to "consider discontinuation in critically ill patients." On the point furthest from anything the trials above measured: "Long-term cardiovascular safety of EGRIFTA WR has not been established." The label's most common adverse reactions, over 5% of patients, are "Arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia."
What GLP-1-class agents do to visceral fat, liver fat and lean mass
This evidence base covers a different population: people with obesity or type 2 diabetes, not HIV-associated lipodystrophy.
- Design
- Systematic review, 35 RCTs of liraglutide, semaglutide, tirzepatide or dulaglutide
- Key finding
- Weight loss "consistently accompanied by reductions in total fat mass and visceral adiposity"; muscle-related losses varied widely
- Design
- Meta-analysis, 20 RCTs, 15,782 participants
- Key finding
- Lean mass was 25% to 39% of total weight lost with incretin agonists (semaglutide 35.2%, tirzepatide 25.4%, liraglutide 26.8%)
- Design
- 296 adults with type 2 diabetes, MRI at baseline and week 52
- Key finding
- Liver fat -8.09% with pooled tirzepatide 10 and 15 mg vs -3.38% with insulin degludec (difference -4.71%, 95% CI -6.72 to -2.70, p < 0.0001), from a mean baseline of 15.71%
- Design
- SURPASS-3 MRI population vs sex- and BMI-matched UK Biobank virtual control groups
- Key finding
- z-VAT -0.18 and z-liver fat -0.54, a shift beyond what weight change alone predicts
- Design
- 98 participants, liver fat 10% or more, 48 weeks
- Key finding
- Liver fat -42.9% to -82.4% across doses vs +0.3% placebo (all P < 0.001)
Batsis et al. 2026 (table above) covered a median duration of 26 weeks and a median 78 participants per trial, applying benchmarks of roughly 25% of weight lost as fat-free mass or lean soft tissue and roughly 15% as skeletal muscle, against which its trials varied widely.
Eisa and Barood 2026 (table above) found lifestyle intervention alone lost 26.2% of weight as lean mass (p = 0.42 against the incretin figure), while lifestyle plus resistance training brought that down to 17.5%. The community's stacking rationale, below, rests on the contrast between that 25% to 39% lean-mass share and tesamorelin's meta-analyzed lean-mass gain of about 1.4 kg.
On liver fat, the SURPASS-3 MRI substudy (Gastaldelli et al. 2022, table above) also found tirzepatide reduced VAT and abdominal subcutaneous fat volumes against insulin degludec, with liver-fat reduction correlating with VAT reduction (rho 0.29) and weight loss (rho 0.34). Cariou et al. 2024 revisited the same population against sex- and BMI-matched UK Biobank virtual control groups, finding the shift in fat distribution (table above) went beyond what weight change alone would predict.
Retatrutide's liver-fat data (Sanyal et al. 2024, Nature Medicine, table above) comes from a 48-week phase 2a MASLD substudy of once-weekly retatrutide across four dose groups or placebo, with liver fat measured at 24 weeks. Normal liver fat (below 5%) was reached by 27%, 52%, 79% and 86% across the ascending dose groups, against 0% with placebo, and "LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures."
Why the stack sounds logical
Putting the two evidence bases side by side produces a rationale that sounds coherent, and it is the rationale the community states directly in threads like "6 Month Retatrutide + Tesamorelin" cited above. Tesamorelin's trials show a VAT-selective effect, with "no change in limb or abdominal SC fat" (Falutz 2010) and "no significant effects on abdominal sc adipose tissue" (Makimura 2012), plus a meta-analyzed lean-mass gain of about 1.4 kg. GLP-1-class agents, by contrast, reduce total fat mass, including visceral and liver fat, but 25% to 39% of the weight lost is lean mass (Eisa 2026). From those two separate findings the community derives two questions: whether tesamorelin's lean-mass gain would appear at all in someone losing weight on a GLP-1-class agent, and whether a VAT-selective effect would still show up in a visceral depot that is already shrinking. Neither has been tested.
That is a rationale built from two separate evidence bases studied in two different populations, not a result. Nothing above establishes that tesamorelin's lean-mass gain would transfer into someone already on a GLP-1-class agent, that its VAT effect would add to an already-shrinking visceral depot rather than plateau, or that liver fat, which fell in trials of both classes, would respond additively. The adverse-effect profiles also differ: tesamorelin's trials report arthralgia, myalgia, paresthesia and injection-site reactions (Badran 2026), while incretin agents' adverse effects are mainly gastrointestinal. How the two profiles behave together is untested and is the subject of the next section.
The questions no trial has answered
Several interaction points are physiologically plausible, without any trial measuring what happens when they occur together.
Glucose can move in opposite directions. Tesamorelin transiently raised fasting glucose at 2 weeks in Stanley 2014 (9 mg/dL versus 2 mg/dL with placebo), while Falutz 2010 and Makimura 2012 reported no change in glucose parameters, and its label instructs "evaluate glucose prior to and during therapy." The GLP-1-class trials cited here were run in type 2 diabetes (Gastaldelli 2022) or obesity, where lowering glucose is part of the treatment goal. Whether the two effects offset, and by how much, has not been studied.
IGF-1 rose in the tesamorelin trials cited here that report it (Falutz 2010, P < 0.001; Makimura 2012, +92 µg/L), and the label instructs monitoring, with a note to "consider discontinuing in patients with persistent elevations." No GLP-1-class trial cited here reports IGF-1 as an outcome.
Fluid retention and arthralgia are tesamorelin-specific signals with no counterpart above. The label states fluid retention "may include edema, arthralgia, and carpal tunnel syndrome," appearing in its most common adverse reactions (over 5%) and in the Badran 2026 adverse-event list alongside myalgia, paresthesia and injection-site reactions.
Hypersensitivity is a named label warning: "hypersensitivity reactions have occurred in clinical trials." The hospitalization thread and the "borderline anaphylactic" reply, described above, are self-reports involving multiple concurrent agents, not evidence of an interaction, but they sit next to a warning that exists independently of any stacking question.
Long-term cardiovascular safety is a gap tesamorelin's own label acknowledges: "Long-term cardiovascular safety of EGRIFTA WR has not been established," predating any combination question.
The population mismatch runs through every point above: every trial except Makimura 2012 was run in HIV-associated lipodystrophy, not in adults on a GLP-1-class agent, the population actually asking.
Finally, Ditta 2026 flagged a discontinuation signal on tesamorelin alone: "growth hormone-related adverse effects and higher discontinuation rates (RR 2.25, 95% CI 0.98 to 5.17, p = 0.06) were observed," with "limited data on long-term safety, optimal dosing strategies, and durability of treatment effects" cited as reason for caution. The discontinuation difference did not reach statistical significance (the confidence interval crosses 1), so it is a signal, not an established effect, and it was reported for tesamorelin by itself.
What the community reports, and what it cannot show
Set against the trial data above, the community's numbers describe interest and self-reported outcomes, not evidence. Across all 2,216 tesamorelin posts, 277 claim a noticed result and 70 report no effect, with no imaging, no control group and, in most threads, more than one intervention started together. The 57 stack posts mentioning joint pain, water retention, carpal tunnel or numbness line up with the label's fluid-retention and arthralgia warnings without any thread establishing which agent caused it.
The two adverse-reaction threads cited earlier deserve to be read next to the label rather than dismissed or treated as proof. Both are consistent with the hypersensitivity reactions tesamorelin's own label already discloses: the hospitalization account followed a restart of tesamorelin together with other peptides, while the "borderline anaphylactic" reply describes the first tesamorelin injections without naming another agent. Neither establishes that a GLP-1-class agent taken alongside it changed the risk, severity or presentation. A single account with multiple concurrent inputs cannot assign cause to any one of them.
What a real answer would need
Answering the combination question, rather than reasoning from two separate evidence bases, would require a trial nobody has run: a randomized factorial design with four arms (a GLP-1-class agent alone, tesamorelin alone, both together, and placebo), imaging matching what each drug's own literature already uses (MRI or CT for visceral fat, MRI-PDFF for liver fat, DXA for lean mass), glucose and IGF-1 monitored throughout, run for at least 26 to 52 weeks, in the population actually stacking these agents: adults with obesity, not HIV-associated lipodystrophy. No such trial is registered on ClinicalTrials.gov as of this search.
- What is known
- VAT reductions in the five HIV-associated-lipodystrophy RCTs pooled by Badran 2026 (VAT MD -27.71 cm2), plus the one non-HIV RCT in obese adults with reduced GH secretion (Makimura 2012, treatment effect -35 cm2)
- What is not known
- Any effect in adults already losing visceral fat on a GLP-1-class agent
- What is known
- Consistent reductions in total fat mass and visceral adiposity across 35 RCTs (Batsis 2026); liver fat and VAT reductions on MRI (Gastaldelli 2022; Sanyal 2024)
- What is not known
- Whether adding a GHRH analogue changes any of these outcomes
- What is known
- Tesamorelin +1.42 kg in both 2026 meta-analyses; 25% to 39% of weight lost as lean mass with incretins (Eisa 2026)
- What is not known
- Whether the two effects offset each other in the same person
- What is known
- Transient fasting-glucose rise in Stanley 2014, none in Makimura 2012; IGF-1 rises with tesamorelin; label requires monitoring both
- What is not known
- The net direction of glucose and IGF-1 under the combination
- What is known
- Arthralgia, edema, paresthesia, injection-site and hypersensitivity reactions for tesamorelin; non-significant discontinuation signal (Ditta 2026)
- What is not known
- Whether any of these change in frequency or severity next to a GLP-1-class agent
- What is known
- ClinicalTrials.gov, August 2026: none registered
- What is not known
- Everything above
Where these products sit in our catalog
GHRH analogue for GH-axis research
Triple agonist, GLP-1-class research
For tesamorelin's own visceral-fat, liver-fat and cognition data, see our dedicated review. For GH-axis side effects, see our side-effect review. For what IGF-1 measures, see our IGF-1 explainer. For GHRH vs GHRP, see our comparison article.
Frequently asked questions
Sources
- Falutz J, Potvin D, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53:311-22. PMID 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Stanley TL, Feldpausch MN, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380-9. PMID 25038357. https://pubmed.ncbi.nlm.nih.gov/25038357/
- Stanley TL, Fourman LT, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6:e821-e830. PMID 31611038. https://pubmed.ncbi.nlm.nih.gov/31611038/
- Makimura H, Feldpausch MN, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:4769-79. PMID 23015655. https://pubmed.ncbi.nlm.nih.gov/23015655/
- Lake JE, La K, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35:1395-1402. PMID 33756511. https://pubmed.ncbi.nlm.nih.gov/33756511/
- Adrian S, Scherzinger A, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8:154-159. PMID 31237318. https://pubmed.ncbi.nlm.nih.gov/31237318/
- Badran AS, Helal A, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20:2-12. PMID 41545261. https://pubmed.ncbi.nlm.nih.gov/41545261/
- Ditta AM, Naeem RM, et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care. 2026;25. PMID 42538058. https://pubmed.ncbi.nlm.nih.gov/42538058/
- Theratechnologies Inc. EGRIFTA WR (tesamorelin) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- Batsis JA, Gavras A, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026;179:996-1013. PMID 41996180. https://pubmed.ncbi.nlm.nih.gov/41996180/
- Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026;28:4818-4827. PMID 41877354. https://pubmed.ncbi.nlm.nih.gov/41877354/
- Gastaldelli A, Cusi K, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Lancet Diabetes Endocrinol. 2022;10:393-406. PMID 35468325. https://pubmed.ncbi.nlm.nih.gov/35468325/
- Cariou B, Linge J, et al. Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. Diabetes Obes Metab. 2024;26:2446-2455. PMID 38528819. https://pubmed.ncbi.nlm.nih.gov/38528819/
- Sanyal AJ, Kaplan LM, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048. PMID 38858523. https://pubmed.ncbi.nlm.nih.gov/38858523/
- Reddit corpus extraction, 12 months to August 2026 (our own count: 2,216 tesamorelin posts, 1,237 with a GLP-1-class mention); threads cited by title, not linked.
- ClinicalTrials.gov search, August 2026: tesamorelin combined with semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1: no registered study. https://clinicaltrials.gov/
Research use only. Tesamorelin, retatrutide and the other peptides discussed in this article are supplied for laboratory research, not for human or animal administration, and not as a medicine. Nothing in this article is a dosing, protocol, or treatment instruction, and nothing here claims that combining tesamorelin with a GLP-1-class agent is effective, safe, additive or synergistic.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.